MedTrace Logo

Impact of Chemotherapy Dose Reductions on Survival Outcomes Among Older NSCLC Patients Without Actionable Mutations

NCT07369596 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2026-06-02

No results posted yet for this study

Summary

Evidence suggests that appropriately selected older adults can tolerate standard-dose chemotherapy and achieve survival outcomes comparable to younger patients. However, older adults are usually under-represented in clinical trials and often receive reduced doses of chemotherapy due to concerns regarding age-related frailty, polypharmacy, and toxicity.

This study seeks to evaluate chemotherapy dosing patterns and associated survival outcomes in older patients.

Conditions

  • Non Small Cell Lung Carcinoma NSCLC

Interventions

OTHER

Progression free survival

PFS

OTHER

Overall survival

OS

Sponsors & Collaborators

  • University of Malaya

    lead OTHER

Principal Investigators

  • Mau Ern Poh, MBBS · University of Malaya

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2026-12-31
Completion
2026-12-31

Countries

  • Hong Kong
  • Malaysia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07369596 on ClinicalTrials.gov